home

Therapy focus – Private companies in the Alzheimer's spotlight

R&Depvantage2016-04-15 17:25 Read   66

Last week’s decision by AstraZeneca and Lilly to advance their BACE inhibitor into phase III studies gives the stock market a new late-stage, potentially disease-modifying Alzheimer’s programme on which to fixate alongside Lilly’s solanezumab and Biogen’s aducanumab.

Sanofi opens UK bioscience partnering office

R&Dpmlive2016-04-15 10:56 Read   76

Sanofi has opened an office in Stevenage that will try to foster partnerships with life science research groups in the UK.

Priority review for Keytruda in head and neck cancer

R&Dpmlive2016-04-15 10:38 Read   150

The FDA has started a priority review of Merck & Co's PD-1 inhibitor Keytruda in head and neck cancer, raising the prospect of a third indication for the fast-growing immuno-oncology drug.

Bristol-Myers expands I/O hub, may hire up to 150 more for discovery team

R&Dfiercebiotech2016-04-15 10:12 Read   99

Bristol-Myers Squibb is once again growing its footprint in the fast-growing immuno-oncology R&D world. The biopharma company inked a lease on the third and final facility BioMed Realty owns at Woodside Technology Park in Redwood City, CA, opening the door to an expansion of its biologics discovery team, set to grow from the 250 now employed at the hub to as many as 400 with the add-on.

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon

R&DAmpliPhi2016-04-15 10:06 Read   87

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon.

Bio Products Laboratory, Ltd Announces FDA Submission of Biologics License Supplement for Gammaplex 10%

R&DBio Products Laboratory2016-04-14 15:23 Read   263

Bio Products Laboratory, Limited (BPL), a leading manufacturer of plasma-derived protein therapies, today announced the submission of a Biologics License Supplement (BLS) to the U.S. Food and Drug Administration (FDA) for the use of Gammaplex 10%, Immune Globulin Intravenous (Human) in patients with primary immunodeficiencies.

With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets

R&Dxconomy2016-04-14 13:43 Read   72

Harvard University chemical biologist and serial entrepreneur Greg Verdine has spent more than a decade trying to come up with different solutions for one critical problem in biotech: The majority of would-be drug targets are out of reach of existing technologies.

Pharma Nabs $68M, Crossover Backers for Eye Drug Push

R&Dxconomy2016-04-14 13:38 Read   77

It’s been a common sight over the past few years for a biotech startup to bring a bunch of “crossover” investors—who invest in both public and private companies—into the mix before taking a crack at an IPO.

Merck KGaA loses FDA nod for fertility drug

R&Dfiercepharma2016-04-14 11:13 Read   84

It's been more than 10 years since the FDA signed off on Merck KGaA's fertility drug Luveris. But now, after the company failed to conduct a postmarketing trial, the FDA has yanked the drug's approval at the German pharma's request.

PAREXEL And EMC Form Alliance To Provide Cloud-Based Document And Regulatory Information Management Services

R&Drealwire2016-04-14 10:27 Read   82

PAREXEL enhances its Regulatory Cloud; leverages EMC® Documentum® for Life Sciences software solution suite to offer an end-to-end regulatory solution

Brain on LSD revealed: First scans show how the drug affects the brain

R&Dsciencedaily2016-04-14 10:20 Read   71

For the first time, researchers have visualized the effects of LSD on the human brain. In a series of experiments, scientists have gained a glimpse into how the psychedelic compound affects brain activity. The team administered LSD (Lysergic acid diethylamide) to 20 healthy volunteers in a specialist research centre and used various leading-edge and complementary brain scanning techniques to visualize how LSD alters the way the brain works.

Baylor scientists ID dendritic cells as new cancer therapy targets

R&Dfiercebiotech2016-04-14 09:33 Read   63

 One of the ways cancer cells are effective at suppressing the host immune response is by turning off a surface protein called CTLA-4.